Macrolide-resistant methicillin-resistant Staphylococcus aureus (MAC-MRSA) is one of the most clinically relevant pathogens due to its significant ability of resistance acquisition to different antimicrobial agents. This study aimed to evaluate antimicrobial susceptibility and the use of different combinations of azithromycin with other antibiotics for combating MAC resistance. Seventy-two Staphylococci (38.5%) (n = 187), showed resistance to MACs; of these, 53 isolates (73.6%, n = 72) were S. aureus and 19 (26.4%, n = 72) were coagulase-negative staphylococci (CoNS). Out of the 53 S. aureus and 19 CoNS isolates, 38 (71.7%, n = 53) and 9 (47.4%, n = 19) were MRSA and methicillin-resistant CoNS, respectively. The constitutive MACs, lincosamides and streptogramin-B (cMLS) comprised the predominant phenotype among S. aureus isolates (54.7%) and CoNS isolates (78.9%). The PCR analysis showed that the ermC gene was the most prevalent (79.2%), followed by msrA (48.6%), and ermA (31.9%). Azithromycin combinations with either linezolid, ceftriaxone, gentamicin, or cefotaxime provided synergy in 42.1%, 44.7%, 31.6% and 7.9% of the 38 MAC-MRSA isolates, respectively. Statistical analysis showed significant association between certain MAC resistance genotypes and the synergistic effect of certain azithromycin combinations (p value < 0.05). In conclusion, azithromycin combinations with either linezolid, or ceftriaxone showed synergism in most of the MAC-resistant MRSA clinical isolates.
Macrolide resistance of staphylococci has risen dramatically in recent years generating a real challenge for their treatment as therapeutic options have become very limited. In this study, an antibiogram analysis of one hundred and fifty Staphylococcus sp. isolates collected from various clinical specimens, against erythromycin, azithromycin, spiramycin, and clindamycin was carried out. Out of the 150 collected Staphylococcus sp. isolates, 54 isolates (36%) showed resistance to two or more of the tested macrolides. Inducible macrolide, lincosamides and streptogramin type B resistance phenotype (iMLS) using D-test was identified in 15 of the resistant isolates (27.8%). Molecular detection of major genes coding for macrolide resistance, including erythromycin ribosomal methylase (ermA and ermC), and macrolidestreptogramin resistance gene (msrA) was carried out using PCR. It was found that 51.8, 37.1 and 11.1% of the resistant isolates carried one, two and three types of the resistance genes, respectively. However, ermC was the most frequently occurring gene (81.5%), followed by the msrA gene (42.6%), then the ermA gene (35.2%). In conclusion, the genotypic analysis revealed that the majority of the tested isolates harbored two or more macrolide resistance-coding genes where 36% displayed resistance to at least two of the most common macrolide antibiotics used in the treatment of such important pathogens particularly in patients exhibiting hypersensitivity to penicillins according to several international guidelines. Therefore, it is crucial to carry out more epidemiologic studies to clearly understand the problem of increasing macrolide resistance among Staphylococci and to implement new guidelines for the treatment of such important pathogens, particularly in Egypt.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.